The Lancet Diabetes & Endocrinology (the-lancet-diabetes-and-endocrinology)

Journal positioning

The Lancet Diabetes & Endocrinology is a Lancet specialty journal for high-impact clinical and population research across diabetes, obesity, endocrine, and metabolic medicine — type 1 and type 2 diabetes, obesity and metabolic disease, thyroid, adrenal, pituitary, bone and mineral, and reproductive endocrinology. It favors major randomized trials, large prospective cohorts, and population/epidemiological analyses with clear international clinical or policy consequence, with a strong emphasis on rigorous design, hard or patient-important outcomes, and generalizable populations. Small single-center endocrine series, mechanistic/basic-science work without a clinical endpoint, and routine biomarker-association studies are a weak fit and belong in a broad clinical-endocrinology or basic-science venue. This skill is a fit / venue-selection / re-framing aid; it is not clinical or regulatory advice and does not replace the journal's current instructions for authors. Before submitting, re-check the live The Lancet Diabetes & Endocrinology author instructions.

When to trigger

• The author names The Lancet Diabetes & Endocrinology for a diabetes, endocrine, or

metabolic clinical/population study and wants a fit/framing check.

• A trial or large cohort must be re-framed around an international, practice-changing

diabetes or endocrine question.

• The author is choosing between The Lancet Diabetes & Endocrinology, the Journal of

Clinical Endocrinology & Metabolism, Diabetologia, and general medicine.

• The author needs the journal's reporting-guideline, registration, and desk-reject

expectations for metabolic/endocrine evidence.

Scope & topic fit

• Randomized trials in diabetes pharmacotherapy, glucose-lowering and cardiovascular-/

renal-outcome trials, and obesity/metabolic interventions.

• Large prospective cohorts and high-quality observational studies on diabetes/obesity

burden, complications, prognosis, or treatment effect at scale.

• Endocrine trials and cohorts (thyroid, adrenal, pituitary, bone/mineral, reproductive)

with patient-important outcomes.

• Population, epidemiological, and health-policy studies on metabolic disease with

international or equity relevance.

• Pragmatic, implementation, and prevention trials, and well-powered diagnostic studies,

in diabetes/endocrinology.

• Systematic reviews and meta-analyses resolving a focused, clinically consequential

metabolic or endocrine question.

Method & evidence bar

• Trials must be adequately powered with prespecified, patient-important primary

outcomes (cardiovascular/renal events, mortality, body-weight or glycaemic endpoints with clinical anchoring); surrogate-only endpoints need strong justification.

• The applicable reporting guideline and completed checklist are expected: CONSORT for

trials, STROBE for observational studies, PRISMA for systematic reviews, STARD for diagnostic accuracy.

• Trials require prospective registration; the registration number, protocol, and

statistical-analysis plan are expected.

• Observational and Mendelian-randomization claims must address confounding, pleiotropy,

selection bias, and missing data; causal language must match the design.

• Effect estimates need confidence intervals and absolute as well as relative measures;

generalizability across populations and health systems should be argued.

• Multi-center, international, and registry/linkage-scale evidence strengthens fit;

single-center metabolic series rarely clear the bar.

Structure & house style

• Lancet specialty format with a structured summary and a Research in context /

evidence-before-this-study panel; re-check current article types and limits on the live guide.

• The introduction frames the international clinical or policy gap in metabolic/endocrine

care; the discussion states the practice consequence and limitations plainly.

• A CONSORT/STROBE/PRISMA flow diagram is expected where applicable; tables/figures

follow Lancet statistical-reporting standards.

• The role of the funding source statement and a data-sharing statement are expected;

appendices carry protocol, full statistical methods, and additional analyses.

Official-submission checklist

• Before giving submission-ready advice, read ../../resources/source-basis.md and

../../resources/official-source-map.md; start from the ICMJE/EQUATOR and Lancet anchors, then cite the current The Lancet Diabetes & Endocrinology page you checked.

• Search the live site for "The Lancet Diabetes Endocrinology information for authors"

and follow the current version.

• Re-check article types, structured-summary and Research in context format, and

word/reference/figure limits.

• Confirm trial registration, the reporting checklist (CONSORT/STROBE/PRISMA/STARD),

protocol/SAP, the role-of-funding-source statement, and data-sharing statement.

• Re-check IRB/ethics and consent, ICMJE authorship and conflict-of-interest disclosure,

funding, and AI-use disclosure.

• If the live official instructions conflict with this skill, the official instructions

win.

Pre-submission self-check

• [ ] The study answers an international, practice-changing diabetes/endocrine/metabolic question.
• [ ] The primary outcome is prespecified and patient-important; the study is adequately powered.
• [ ] The correct reporting checklist (CONSORT/STROBE/PRISMA/STARD) is completed and attached.
• [ ] Trials are prospectively registered with the number in the manuscript; protocol/SAP provided.
• [ ] Confounding, pleiotropy/selection bias, and missing data are addressed; causal language matches the design.
• [ ] IRB/consent, ICMJE disclosures, role-of-funding-source, and a data-sharing statement are prepared.

Common desk-reject triggers

• Single-center or underpowered diabetes/endocrine studies with limited generalizability and no practice change.
• Mechanistic or basic-metabolism work with no clinical endpoint, better suited to a basic-science venue.
• Surrogate-only endpoints (e.g., HbA1c change with no clinical anchoring) presented as definitive.
• Routine biomarker- or genetic-association studies without practice-changing consequence.
• Missing trial registration, protocol, or the required reporting checklist.
• Narrow scope without international clinical or policy relevance.

Re-routing decision

• Broad clinical endocrinology (thyroid/adrenal/pituitary/bone) without practice-changing scale → journal-of-clinical-endocrinology-and-metabolism (Endocrine Society, broad clinical).
• Diabetes work including basic/translational science → diabetologia (EASD, diabetes incl. basic science).
• Population/policy framing without a clinical metabolic endpoint → the-lancet-public-health.
• Endocrine-related respiratory or critical-care comorbidity dominant → the-lancet-respiratory-medicine.
• Broad, practice-changing significance beyond the specialty → general medicine (jama / NEJM / The Lancet in the natural-science bundle).

Output format

[Fit] High / Medium / Low (one-line reason)
[Target] The Lancet Diabetes & Endocrinology
[Specialty tags] <2–3 closest diabetes/endocrine/metabolic topics>
[Study design / reporting guideline] <RCT-CONSORT / cohort-STROBE / review-PRISMA / diagnostic-STARD>
[Method/evidence] <power, design, registration, generalizability — does it clear the major-trial bar?>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <article type / registration / checklist / role-of-funding / ethics / disclosures>
[Re-route suggestion] <if not a fit, a better-matched venue>